The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis.
 
Daniel Adam Breadner
No Relationships to Disclose
 
Stephen Welch
Honoraria - Amgen; Celgene; Roche; Sanofi
Consulting or Advisory Role - Amgen; Roche
Research Funding - Amgen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Roche
 
Denis Soulieres
No Relationships to Disclose
 
Michael Susmoy Sanatani
No Relationships to Disclose
 
Paul Klimo
No Relationships to Disclose
 
Mary J. MacKenzie
No Relationships to Disclose
 
Frances Whiston
No Relationships to Disclose
 
Larry Stitt
No Relationships to Disclose
 
Anne O'Connell
No Relationships to Disclose
 
Mark David Vincent
Leadership - Aptose Biosciences
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Lilly; Merck; Novartis; Roche Canada; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; Novartis; Roche
Speakers' Bureau - Lilly
Patents, Royalties, Other Intellectual Property - CEO Sarissa Inc., and patent holder of two non-commercialized patents
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Lilly; Roche Canada